Share Price, page-477

https://www.reuters.com/legal/litigation/former-fda-adviser-calls-wider-probe-into-biogen-alzheimers-drug-approval-2021-07-20/

Biogen did not submit an application at first, because the studies on the drug were not conclusive that it was effective. Then they went back and "found" that one of the studies at high doses showed some promise. Applied to the FDA and the drug was passed, despite not showing a statistical significant improvement in alzheimers.

https://www.abc.net.au/news/2013-11-27/growing-concerns-over-side-effects-of-seroquel/5120554

Seroquel being approved by the FDA, despite Astrazenica hiding its severe side effect profile. It now just has to have a warning on the label and during advertisements, so basically a slap on the wrist...side effects - death, heart complications and diabetes.

If anyone thinks the NDA for trof will not be approved, then the argument must be other than the side effect profile. If anyone has an argument, I would love to hear why Trofinitide getting approval is still a risk.

The larger holders just want to make their profits off of as least risk as humanely possible, which is what I would also probably do if I had that many shares TBH. But I invite them to exit at $8 next year, while we still HOLD!

Omicron isnt really helping at the moment either.